Efficacy of antibody drug conjugate (ADC) by mRNA expression of targeted genes in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN-2

被引：0

作者：

Fujisawa, T. ^{[1
]}

Nakamura, Y. ^{[1
]}

Sakamoto, N. ^{[2
]}

Hashimoto, T. ^{[1
]}

Nagamine, M. ^{[3
]}

Kuwata, T. ^{[4
]}

Ishii, G. ^{[3
]}

Yamashita, R. ^{[5
]}

Morizane, C. ^{[6
]}

Nonomura, N. ^{[7
]}

Iwata, H. ^{[8
]}

Okano, S. ^{[9
]}

Watari, H. ^{[10
]}

Namikawa, K. ^{[11
]}

Shibuki, T. ^{[1
]}

Imai-Sumida, M. ^{[1
]}

Bando, H. ^{[1
]}

Radovich, M. ^{[12
]}

Sledge, G. ^{[13
]}

Yoshino, T. ^{[1
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Promot Drug & Diagnost Dev, Kashiwa, Chiba, Japan

[2] Natl Canc Ctr Exploratory Oncol Res & Clin Trial, Div Pathol, Kashiwa, Chiba, Japan

[3] Natl Canc Ctr Hosp East, Dept Pathol & Clin Labs, Kashiwa, Chiba, Japan

[4] Natl Canc Ctr Hosp East, Dept Genet Med & Serv, Kashiwa, Chiba, Japan

[5] Natl Canc Ctr Hosp East, Div Translat Informat, Kashiwa, Chiba, Japan

[6] NCCH Natl Canc Ctr Hosp, Dept Hepatobiliary & Pancreat Oncol, Tsukiji Campus,Chuo Ku, Tokyo, Japan

[7] Osaka Univ, Fac Med, Grad Sch Med, Urol Dept, Suita, Osaka, Japan

[8] Aichi Canc Ctr Hosp, Breast Oncol Dept, Nagoya, Aichi, Japan

[9] Natl Canc Ctr Hosp East, Head & Neck Med Oncol Dept, Kashiwa, Chiba, Japan

[10] Hokkaido Univ Hosp, Hematol Oncol, Sapporo, Hokkaido, Japan

[11] NCCH Natl Canc Ctr Hosp, Dermatol Oncol Dept, Chuo Ku, Tokyo, Japan

[12] Caris Life Sci, Precis Med, Phoenix, AZ USA

[13] Caris Life Sci, Lab & Specimen Receiving, Phoenix, AZ USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.2206

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

201P

引用

页码：S297 / S298

页数：2

共 50 条

[31] Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors.
Konecny, Gottfried E.
Hendrickson, Andrea Elisabeth Wahner
Winterhoff, Boris
Chander, Cinthiya
Bilic, Sanela
Davenport, Simon
Chung, Adrine
Miller, Lei-Lani
Press, Michael F.
Letrent, Stephen P.
Slamon, Dennis J.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[32] Efficacy and safety of sacituzumab govitecan Trop-2-targeted antibody-drug conjugate in solid tumors and UGT1A1*28 polymorphism: a systematic review and meta-analysis
Rehena Sultana
Sylvia Chen
Elaine Hsuen Lim
Rebecca Dent
Balram Chowbay
BJC Reports, 2 (1):
[33] A FIRST-IN-HUMAN TRIAL OF AN INTEGRIN BETA-6 TARGETED ANTIBODY-DRUG CONJUGATE (ADC), SGNB6A, IN PATIENTS WITH ADVANCED SOLID TUMORS: INTERIM RESULTS OF A PHASE 1 STUDY (SGNB6A-001)
Hollebecque, Antoine
Lopez, Juanita
Piha-Paul, Sarina
Dowlati, Afshin
Patnaik, Amita
Galvao, Vladimir
Buckorny, Bruno
Sehgal, Kartik
Kingsley, Edwin
Sanborn, Rachel
Peters, Solange
Sun, Yan
Patilea-Vrana, Gabriela
Nazarenko, Natalya
Calvo, Emiliano
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A763 - A763
[34] NBE-002: A novel anthracycline-based antibody-drug conjugate (ADC) targeting ROR1 for the treatment of advanced solid tumors-A phase 1/2 clinical trial.
Tolcher, Anthony W.
Meric-Bernstam, Funda
McKean, Meredith
Beerli, Roger R.
Waldmeier, Lorenz
Gebleux, Remy
Hellmann, Ina
Chrom, Pawel
Grawunder, Ulf
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[35] A novel, highly potent HER2-targeted antibody-drug conjugate (ADC) for the treatment of low HER2-expressing tumors and combination with trastuzumab-based regimens in HER2-driven tumors
Bergstrom, Donald A.
Bodyak, Natalya
Yurkovetskiy, Alex
Park, Peter U.
DeVit, Michael
Yin, Mao
Poling, Laura
Thomas, Joshua D.
Gumerov, Dmitry
Xiao, Dongmei
Ter-Ovanesyan, Elena
Qin, LiuLiang
Uttard, Alex
Johnson, Alex
Lowinger, Timothy B.
CANCER RESEARCH, 2015, 75
[36] Preliminary results from a first-in-human study of ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients with locally advanced/ metastatic solid tumors
Ma, Fei
Qiu, Fuming
Tong, Zhongsheng
Wang, Jiani
Tan, Yinuo
Bai, Rui
Zhou, Qing
Xing, Xiaoyan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[37] Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced/metastatic solid tumors
Wang, Jiani
Tong, Zhongsheng
Tan, Yinuo
Shi, Yehui
Wu, Yun
Zhou, Qing
Xing, Xiaoyan
Chen, Xiaomei
Qiu, Fuming
Ma, Fei
CELL REPORTS MEDICINE, 2024, 5 (09)
[38] A HER2-targeted Antibody-Drug Conjugate, RC48-ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer
Hong, Xuwei
Chen, Xu
Wang, Hongjin
Xu, Qingchun
Xiao, Kanghua
Zhang, Yuanfeng
Chi, Zepai
Liu, Yeqing
Liu, Guangyao
Li, Hong
Fang, Jianmin
Lin, Tianxin
Zhang, Yonghai
ADVANCED SCIENCE, 2023, 10 (32)
[39] SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001)
Hollebecque, Antoine
Lopez, Juanita Suzanne
Piha-Paul, Sarina A.
Dowlati, Afshin
Patnaik, Amita
Galvao, Vladimir
Bockorny, Bruno
Sehgal, Kartik
Kingsley, Ed
Sanborn, Rachel E.
Perez, Cesar Augusto
Peters, Solange
Yan, Mingjin
Nazarenko, Natalya N.
Calvo, Emiliano
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[40] First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors.
Bendell, Johanna
Blumenschein, George
Zinner, Ralph
Hong, David
Jones, Suzanne
Infante, Jeffrey
Burris, Howard
Rajagopalan, Prabhu
Kornacker, Martin
Henderson, David
Kelly, Andrea
Hassan, Raffit
CANCER RESEARCH, 2013, 73 (08)

← 1 2 3 4 5 →